These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22036848)

  • 1. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 2. GLP-1-based therapies: the dilemma of uncertainty.
    Spranger J; Gundert-Remy U; Stammschulte T
    Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
    [No Abstract]   [Full Text] [Related]  

  • 3. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
    Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
    Lando HM; Alattar M; Dua AP
    Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
    Prescrire Int; 2011 Nov; 20(121):267. PubMed ID: 22066314
    [No Abstract]   [Full Text] [Related]  

  • 6. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
    Cohen D
    BMJ; 2013 Feb; 346():f1304. PubMed ID: 23447395
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 9. Journal withdraws article after complaints from drug manufacturers.
    Hawkes N
    BMJ; 2011 Apr; 342():d2335. PubMed ID: 21482597
    [No Abstract]   [Full Text] [Related]  

  • 10. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
    Harja E; Lord J; Skyler JS
    Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatitis associated with incretin-based therapies.
    Iyer SN; Tanenberg RJ; Mendez CE; West RL; Drake AJ
    Diabetes Care; 2013 Apr; 36(4):e49. PubMed ID: 23520376
    [No Abstract]   [Full Text] [Related]  

  • 13. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
    Ryder RE
    Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin intolerance.
    Kargili A; Karakurt F; Kankilic MN; Kankilic ES; Bozkurtl B
    Allergol Immunopathol (Madr); 2010; 38(5):290-1. PubMed ID: 20554368
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
    Tanaka K; Ogawa Y; Shimada S
    J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936
    [No Abstract]   [Full Text] [Related]  

  • 16. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 17. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis/pancreatic cancer.
    Shirakawa J; Terauchi Y
    J Diabetes Investig; 2020 Jul; 11(4):789-791. PubMed ID: 31774618
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Wang Y; Zhao L; Huang Q; Peng Y
    J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.